The Asia Pacific Atopic Dermatitis Drugs Market would witness market growth of 10.1% CAGR during the forecast period (2022-2028).
The atopic dermatitis market is anticipated to grow significantly during the projected period due to the quick development of novel pipeline medications that are anticipated to increase the market's size. Additionally, the expansion of the atopic dermatitis sector and the rise in the demand for novel biologics and product approvals are both expected to support the market's expansion.
The increasing incidence of atopic dermatitis and favorable reimbursement policies in developing nations are additional factors anticipated to fuel market expansion. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the market for atopic dermatitis drugs.
Atopic dermatitis, which first manifested in youth, might also get worse over time. Additionally, the issue is a huge one in emerging nations. The condition exhibits a great deal of variation in terms of clinical seriousness, illness severity, tenacity, response to treatment, and inventiveness on both sides. Reducing skin irritation, along with pruritus and flare anticipation, is a key goal of drug-based infection treatment.
Over the past few decades, the frequency of atopic dermatitis has increased in Asian nations, just like it has elsewhere in the world. This increased frequency in Asian nations has been linked to a number of developments, including rapid urbanization, a move toward more westernized lifestyles, and higher living and educational standards. It is crucial to comprehend the rising disease load in Asian nations as well as the variations among them in terms of epidemiology, diagnostic standards, management, quality of life, and financial burden.
The China market dominated the Asia Pacific Atopic Dermatitis Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,508.9 million by 2028.The Japan market is estimated to grow a CAGR of 9.5% during (2022 - 2028). Additionally, The India market would experience a CAGR of 10.8% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Injectable, Oral and Topical. Based on Class, the market is segmented into Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Atopic Dermatitis Drugs Market is Projected to reach USD 22 Billion by 2028, at a CAGR of 9.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
By Class
- Biologics
- Calcineurin Inhibitors
- Corticosteroids
- PDE4 Inhibitors
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Pfizer Inc.
- Sanofi SA
- AbbVie Inc.
- Galderma S.A.
- Eli Lilly and Company
- Leo Pharma A/S
- Regeneron Pharmaceuticals Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Novartis AG
- Incyte Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Atopic Dermatitis Drugs Market, by Route of Administration
1.4.2 Asia Pacific Atopic Dermatitis Drugs Market, by Class
1.4.3 Asia Pacific Atopic Dermatitis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Acquisition and Mergers
3.2.2 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2018, Sep – 2022, Oct) Leading Players
Chapter 4. Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration
4.1 Asia Pacific Injectable Market by Country
4.2 Asia Pacific Oral Market by Country
4.3 Asia Pacific Topical Market by Country
Chapter 5. Asia Pacific Atopic Dermatitis Drugs Market by Class
5.1 Asia Pacific Biologics Market by Country
5.2 Asia Pacific Calcineurin Inhibitors Market by Country
5.3 Asia Pacific Corticosteroids Market by Country
5.4 Asia Pacific PDE4 Inhibitors Market by Country
5.5 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific Atopic Dermatitis Drugs Market by Country
6.1 China Atopic Dermatitis Drugs Market
6.1.1 China Atopic Dermatitis Drugs Market by Route of Administration
6.1.2 China Atopic Dermatitis Drugs Market by Class
6.2 Japan Atopic Dermatitis Drugs Market
6.2.1 Japan Atopic Dermatitis Drugs Market by Route of Administration
6.2.2 Japan Atopic Dermatitis Drugs Market by Class
6.3 India Atopic Dermatitis Drugs Market
6.3.1 India Atopic Dermatitis Drugs Market by Route of Administration
6.3.2 India Atopic Dermatitis Drugs Market by Class
6.4 South Korea Atopic Dermatitis Drugs Market
6.4.1 South Korea Atopic Dermatitis Drugs Market by Route of Administration
6.4.2 South Korea Atopic Dermatitis Drugs Market by Class
6.5 Singapore Atopic Dermatitis Drugs Market
6.5.1 Singapore Atopic Dermatitis Drugs Market by Route of Administration
6.5.2 Singapore Atopic Dermatitis Drugs Market by Class
6.6 Malaysia Atopic Dermatitis Drugs Market
6.6.1 Malaysia Atopic Dermatitis Drugs Market by Route of Administration
6.6.2 Malaysia Atopic Dermatitis Drugs Market by Class
6.7 Rest of Asia Pacific Atopic Dermatitis Drugs Market
6.7.1 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration
6.7.2 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class
Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Acquisition and Mergers:
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sanofi S.A.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Acquisition and Mergers:
7.4 LEO Pharma A/S
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Acquisition and Mergers:
7.5 Incyte Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Research & Development Expenses
7.5.4 Recent strategies and developments:
7.5.4.1 Approvals and Trials:
7.5.4.2 Acquisition and Mergers:
7.6 AbbVie, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.6.5.2 Acquisition and Mergers:
7.7 Regeneron Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Otsuka Pharmaceutical Co., Ltd.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.9.2.2 Acquisition and Mergers:
7.10. Galderma S.A.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Acquisition and Mergers:
TABLE 1 Asia Pacific Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 2 Asia Pacific Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 3 Acquisition and Mergers– Atopic Dermatitis Drugs Market
TABLE 4 Approvals and trials – Atopic Dermatitis Drugs Market
TABLE 5 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 6 Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 7 Asia Pacific Injectable Market by Country, 2018 - 2021, USD Million
TABLE 8 Asia Pacific Injectable Market by Country, 2022 - 2028, USD Million
TABLE 9 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
TABLE 10 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
TABLE 11 Asia Pacific Topical Market by Country, 2018 - 2021, USD Million
TABLE 12 Asia Pacific Topical Market by Country, 2022 - 2028, USD Million
TABLE 13 Asia Pacific Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 14 Asia Pacific Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 15 Asia Pacific Biologics Market by Country, 2018 - 2021, USD Million
TABLE 16 Asia Pacific Biologics Market by Country, 2022 - 2028, USD Million
TABLE 17 Asia Pacific Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 18 Asia Pacific Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 19 Asia Pacific Corticosteroids Market by Country, 2018 - 2021, USD Million
TABLE 20 Asia Pacific Corticosteroids Market by Country, 2022 - 2028, USD Million
TABLE 21 Asia Pacific PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 22 Asia Pacific PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 23 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
TABLE 24 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
TABLE 25 Asia Pacific Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
TABLE 26 Asia Pacific Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
TABLE 27 China Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 28 China Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 29 China Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 30 China Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 31 China Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 32 China Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 33 Japan Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 34 Japan Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 35 Japan Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 36 Japan Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 37 Japan Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 38 Japan Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 39 India Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 40 India Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 41 India Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 India Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 India Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 44 India Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 45 South Korea Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 46 South Korea Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 47 South Korea Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 48 South Korea Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 49 South Korea Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 50 South Korea Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 51 Singapore Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 52 Singapore Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 53 Singapore Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 54 Singapore Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 55 Singapore Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 56 Singapore Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 57 Malaysia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 58 Malaysia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 59 Malaysia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 60 Malaysia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 61 Malaysia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 62 Malaysia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 63 Rest of Asia Pacific Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 64 Rest of Asia Pacific Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 65 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 68 Rest of Asia Pacific Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 69 Key Information – Pfizer, Inc.
TABLE 70 Key Information – Novartis AG
TABLE 71 Key Information – Sanofi S.A.
TABLE 72 key information – LEO Pharma A/S
TABLE 73 Key Information – INCYTE CORPORATION
TABLE 74 Key information – AbbVie, Inc.
TABLE 75 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 76 Key Information – Eli Lilly And Company
TABLE 77 key information – Otsuka Pharmaceutical Co., Ltd.
TABLE 78 Key Information – Galderma S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, SeP – 2022, Oct) Leading Players
FIG 5 Recent strategies and developments: Pfizer, Inc.
FIG 6 Recent strategies and developments: sanofi s.a.
FIG 7 Recent strategies and developments: leo pharma a/s